压力引起的认知功能和肠道屏障完整性的变化可以通过venlafaxine和共生补充剂来改善
Sarawut Lapmanee1, Nattapon Supkamonseni1, Sakkarin Bhubhanil1
1Department of Basic Medical Sciences, Faculty of Medicine, Siam University, Bangkok, Thailand.
PeerJ
|March 4, 2024
概括
协生菌和文拉法辛减轻了对大脑和肠道的压力影响. 这两种治疗都改善了记忆力,减少了类似抑郁症的行为,并保护了大鼠免受压力诱导的肠道损伤.
科学领域:
- 神经科学是一个神经科学.
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 压力显著影响身体和心理健康,影响大脑和肠道功能.
- 之前的研究表明,文拉法辛 (Vlx) 和协生菌 (Syn) 可减轻压力诱导的行为缺陷.
- 在压力下,Vlx和Syn在肠-大脑轴上的精确机制需要进一步阐明.
研究的目的:
- 研究同生菌和/或文拉法辛治疗对压力大鼠的物理,行为和细胞效应.
- 探索这些干预措施对大脑和肠道功能的影响.
- 了解肠-大脑轴在与压力相关的疾病中的作用.
主要方法:
- 成年雄性Wistar大鼠接受了14天的固定压力.
- 受到压力的老鼠接受了同生菌 (Syn) 和/或文拉法辛 (Vlx) 的补充.
- 评估的参数包括体重,食物/水摄入量,皮质水平,上腺体重,行为,海马细胞死亡,大肠炎症,肠道透性和质细胞衍生的神经营养因子表达.
主要成果:
- Syn和/或Vlx治疗减轻了压力引起的减肥,使摄入量正常化,并降低了皮质水平和上腺体重.
- 治疗改善了类似抑郁症的行为和空间学习-记忆缺陷.
- Syn显著降低了膜炎症和肠道透性,而Syn和Vlx都减轻了海马中因压力引起的神经元细胞死亡.
结论:
- 协生性干预有效地改善了压力诱导的神经细胞死亡,行为障碍和肠道屏障功能障碍.
- 对肠-大脑轴的共生作用与文拉法辛相似.
- 协生菌是一种有希望的治疗策略,通过向肠-大脑轴来管理与压力相关的健康状况.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
163
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
163
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Irritable Bowel Syndrome I: Introduction
273
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
273
Drugs for Treatment of Diarrhea-Predominant IBS
169
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
169
Irritable Bowel Syndrome III: Medical and Nursing Management
204
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
204
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
252
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
252


